Voyager Therapeutics Inc (VYGR) — Capital Reinvestment Ratio

Latest as of March 2024: 0.04x

Voyager Therapeutics Inc (VYGR) has a Capital Reinvestment Ratio of 0.04x as of March 2024, meaning it reinvests 0% of its operating cash flow ($58.77 Million) in capital expenditures ($2.14 Million). Check VYGR goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.04x
Capex / Operating Cash Flow

Operating Cash Flow

$58.77 Million
USD

Capital Expenditures

$2.14 Million
USD

Data as of

Mar 2024
Most recent filing

Voyager Therapeutics Inc Capital Reinvestment Ratio (2015–2023)

This chart tracks Voyager Therapeutics Inc's Capital Reinvestment Ratio across 3 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Voyager Therapeutics Inc.

Annual Capital Reinvestment Ratio for Voyager Therapeutics Inc (2015–2023)

Year-by-year Capital Reinvestment Ratio for Voyager Therapeutics Inc from 2015 to 2023. See Voyager Therapeutics Inc (VYGR) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2023 0.04x $77.92 Million $3.26 Million ▼ -73.7%
2019 0.16x $48.67 Million $7.72 Million ▲ +535.9%
2015 0.02x $41.30 Million $1.03 Million —
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow